NYSE:BIO - Bio-Rad Laboratories Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$295.14 +1.65 (+0.56 %)
(As of 04/23/2019 04:00 PM ET)
Previous Close$293.49
Today's Range$289.03 - $295.98
52-Week Range$220.05 - $345.15
Volume268,400 shs
Average Volume253,971 shs
Market Capitalization$8.79 billion
P/E Ratio50.16
Dividend YieldN/A
Beta1.27
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP09057220
Phone510-724-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.29 billion
Cash Flow$5.9492 per share
Book Value$134.91 per share

Profitability

Net Income$365.61 million

Miscellaneous

Employees8,260
Market Cap$8.79 billion
Next Earnings Date5/8/2019 (Confirmed)
OptionableOptionable

Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How will Bio-Rad Laboratories' stock buyback program work?

Bio-Rad Laboratories declared that its board has initiated a stock buyback program on Wednesday, November 29th 2017, which permits the company to buyback $250,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company's management believes its shares are undervalued.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) issued its quarterly earnings results on Thursday, February, 28th. The medical research company reported $2.13 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.61 by $0.52. The medical research company had revenue of $617.54 million for the quarter, compared to analysts' expectations of $610.65 million. Bio-Rad Laboratories had a return on equity of 3.92% and a net margin of 15.76%. View Bio-Rad Laboratories' Earnings History.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Bio-Rad Laboratories.

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?

Bio-Rad Laboratories updated its FY 2019 earnings guidance on Thursday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.382-2.393 billion, compared to the consensus revenue estimate of $2.34 billion.

What price target have analysts set for BIO?

5 Wall Street analysts have issued 12-month price objectives for Bio-Rad Laboratories' shares. Their forecasts range from $335.00 to $420.00. On average, they anticipate Bio-Rad Laboratories' stock price to reach $359.00 in the next year. This suggests a possible upside of 21.6% from the stock's current price. View Analyst Price Targets for Bio-Rad Laboratories.

What is the consensus analysts' recommendation for Bio-Rad Laboratories?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bio-Rad Laboratories.

What are Wall Street analysts saying about Bio-Rad Laboratories stock?

Here are some recent quotes from research analysts about Bio-Rad Laboratories stock:
  • 1. According to Zacks Investment Research, "Bio-Rad exited 2018 on a solid note. We are encouraged with the year-over-year rise in earnings. Constant currency sales growth at the Clinical Diagnostics segment was impressive. The company also saw strong growth in the Life Science segment and cell biology, droplet Digital PCR, gene expression and antibody product lines. Further, solid revenue growth in geographies like Americas and Asia Pacific buoys optimism. We are also upbeat about the company’s receipt of FDA approval for the QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit. Over the past year, Bio-Rad has outperformed its industry. However, challenges associated with the implementation of the global ERP system raise concerns. Further, Bio-Rad is exposed to risks associated with a weaker global economy and lower reimbursement rates." (3/6/2019)
  • 2. Jefferies Financial Group Inc analysts commented, "We see substantial hidden value in BIO’s droplet digital PCR (ddPCR) franchise that is under-appreciated by investors." (9/24/2018)

Has Bio-Rad Laboratories been receiving favorable news coverage?

News articles about BIO stock have trended positive on Tuesday, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bio-Rad Laboratories earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future.

Who are some of Bio-Rad Laboratories' key competitors?

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), Dynavax Technologies (DVAX), Celgene (CELG), First Solar (FSLR), ImmunoGen (IMGN), Array Biopharma (ARRY) and Exelixis (EXEL).

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the folowing people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 69)
  • Ms. Christine A. Tsingos, Exec. VP & CFO (Age 60)
  • Mr. John Goetz, Consultant (Age 69)
  • Mr. John Hertia, Exec. VP & Pres of Clinical Diagnostics Group (Age 63)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 57)

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Retirement Systems of Alabama (0.09%), Brinker Capital Inc. (0.02%), Virtu Financial LLC (0.02%), Louisiana State Employees Retirement System (0.02%), CenturyLink Investment Management Co (0.02%) and BTR Capital Management Inc. (0.01%). Company insiders that own Bio-Rad Laboratories stock include Annette Tumolo, Christine A Tsingos, Giovanni Magni, James R Stark and Michael Crowley. View Institutional Ownership Trends for Bio-Rad Laboratories.

Which major investors are selling Bio-Rad Laboratories stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including Quantitative Systematic Strategies LLC, Strs Ohio, First Hawaiian Bank and Stewart & Patten Co. LLC. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Annette Tumolo, Christine A Tsingos, James R Stark and Michael Crowley. View Insider Buying and Selling for Bio-Rad Laboratories.

Which major investors are buying Bio-Rad Laboratories stock?

BIO stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Brinker Capital Inc., Nisa Investment Advisors LLC, Eqis Capital Management Inc., Oakbrook Investments LLC, CenturyLink Investment Management Co, First Citizens Bank & Trust Co. and Financial Gravity Wealth Inc.. View Insider Buying and Selling for Bio-Rad Laboratories.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $295.14.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $8.79 billion and generates $2.29 billion in revenue each year. The medical research company earns $365.61 million in net income (profit) each year or $5.84 on an earnings per share basis. Bio-Rad Laboratories employs 8,260 workers across the globe.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is http://www.bio-rad.com.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DR, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]


MarketBeat Community Rating for Bio-Rad Laboratories (NYSE BIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  283 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  568
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe BIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel